Description
(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.\nIC50 value:\nTarget: mAChR The general pharmacol. properties of this drug on the gastrointAppearance:SolidBiological Activity:(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. \nIC50 value:\nTarget: mAChR The general pharmacol. properties of this drug on the gastro